# Multi-omics and their integration in psoriasis research (Review)

**Authors:** Hengyan Zhang, Danping Li, Lijuan Zhu, Heguo Yan, Licong Yang, Xuesong Yang, Ye Zhou

PMC · DOI: 10.3892/mmr.2026.13852 · Molecular Medicine Reports · 2026-03-23

## TL;DR

This review explores how combining different omics data helps understand psoriasis, a skin disease, and could lead to better treatments and biomarkers.

## Contribution

The paper integrates findings from multiple omics layers to provide a comprehensive view of psoriasis pathogenesis.

## Key findings

- Genome-wide studies identified common and region-specific psoriasis susceptibility loci.
- Epigenetic and transcriptional changes regulate psoriasis-related genes and alter the transcriptome.
- Proteomic and metabolomic shifts in skin and plasma offer insights into disease mechanisms and biomarker potential.

## Abstract

Psoriasis is a chronic, immune-mediated skin disorder characterized by keratinocyte hyperproliferation, inflammatory infiltrates and systemic comorbidities. While genetic predisposition and immune dysregulation are established contributors, recent advancements in high-throughput omics technologies have provided deeper insights into the molecular complexity of psoriasis. The present review synthesized findings from various omics layers, genomics, epigenomics, transcriptomics, proteomics, metabolomics and microbiomics, to elucidate their roles in psoriasis pathogenesis. Large-scale genome-wide association studies have identified both common and region-specific susceptibility loci. Epigenetic factors and transcription factors regulate psoriasis-related genes by modulating chromatin accessibility, DNA methylation, non-coding RNAs and direct gene activation/inactivation, thereby reshaping the transcriptome. Genetic and epigenetic influences also drive significant alterations in the proteome and metabolome, both in the skin and plasma, shedding light on disease mechanisms and offering potential for biomarker discovery. While microbiome research in psoriasis remains in its early stages, shifts in skin and gut microbial communities have been observed, suggesting their involvement in disease pathogenesis. Together, the multi-layered insights underscore the future potential of integrated systems approaches to unravel disease mechanisms and support the discovery of clinically actionable biomarkers and therapeutic targets, paving the way for more precise diagnosis and targeted therapeutic development in psoriasis.

## Linked entities

- **Diseases:** psoriasis (MONDO:0005083)

## Full-text entities

- **Genes:** CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, MBD2 (methyl-CpG binding domain protein 2) [NCBI Gene 8932] {aka DMTase, NY-CO-41}, ADAMTSL5 (ADAMTS like 5) [NCBI Gene 339366] {aka THSD6}, CYP2S1 (cytochrome P450 family 2 subfamily S member 1) [NCBI Gene 29785] {aka CYPIIS1}, AIF1 (allograft inflammatory factor 1) [NCBI Gene 199] {aka AIF-1, IBA1, IRT-1, IRT1}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, S100A12 (S100 calcium binding protein A12) [NCBI Gene 6283] {aka CAAF1, CAGC, CGRP, ENRAGE, MRP-6, MRP6}, WNT5A (Wnt family member 5A) [NCBI Gene 7474] {aka hWNT5A}, Bsg (basigin) [NCBI Gene 12215] {aka CD147, EMMPRIN, HT-7}, IFNLR1 (interferon lambda receptor 1) [NCBI Gene 163702] {aka CRF2/12, IFNLR, IL-28R1, IL28RA, LICR2}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, HDAC1 (histone deacetylase 1) [NCBI Gene 3065] {aka GON-10, HD1, KDAC1, RPD3, RPD3L1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CCHCR1 (coiled-coil alpha-helical rod protein 1) [NCBI Gene 54535] {aka C6orf18, HCR, SBP, pg8}, PRPF31 (pre-mRNA processing factor 31) [NCBI Gene 26121] {aka NY-BR-99, PRP31, RP11, SNRNP61}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CDSN (corneodesmosin) [NCBI Gene 1041] {aka HTSS, HTSS1, HYPT2, PSS, PSS1}, CLSTN3 (calsyntenin 3) [NCBI Gene 9746] {aka CDHR14, CSTN3, alcbeta}, Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}, S100A7 (S100 calcium binding protein A7) [NCBI Gene 6278] {aka PSOR1, S100A7c}, IL23R (interleukin 23 receptor) [NCBI Gene 149233] {aka PSORS7}, TNFAIP3 (TNF alpha induced protein 3) [NCBI Gene 7128] {aka A20, AIFBL1, AISBL, OTUD7C, TNFA1P2}, ERAP2 (endoplasmic reticulum aminopeptidase 2) [NCBI Gene 64167] {aka L-RAP, LRAP}, S100A9 (S100 calcium binding protein A9) [NCBI Gene 6280] {aka 60B8AG, CAGB, CFAG, CGLB, L1AG, LIAG}, SERPINF1 (serpin family F member 1) [NCBI Gene 5176] {aka EPC-1, OI12, OI6, PEDF, PIG35}, Il23a (interleukin 23, alpha subunit p19) [NCBI Gene 83430] {aka IL-23, p19}, PRF1 (perforin 1) [NCBI Gene 5551] {aka HPLH2, P1, PFP}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, KDM6B (lysine demethylase 6B) [NCBI Gene 23135] {aka JMJD3, NEDCFSA, NEDSST}, NFATC1 (nuclear factor of activated T cells 1) [NCBI Gene 4772] {aka NF-ATC, NF-ATc1.2, NFAT2, NFATc}, NEO1 (neogenin 1) [NCBI Gene 4756] {aka IGDCC2, NGN, NTN1R2}, Ccnd1 (cyclin D1) [NCBI Gene 12443] {aka CycD1, Cyl-1, PRAD1, bcl-1, cD1}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, Il22 (interleukin 22) [NCBI Gene 50929] {aka IL-22, IL-22a, ILTIFa, If2b1, Iltif}, HDAC9 (histone deacetylase 9) [NCBI Gene 9734] {aka HD7, HD7b, HD9, HDAC, HDAC7B, HDAC9B}, CAMP (cathelicidin antimicrobial peptide) [NCBI Gene 820] {aka CAP-18, CAP18, CRAMP, FALL-39, FALL39, HSD26}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, GJB2 (gap junction protein beta 2) [NCBI Gene 2706] {aka BAPS, CX26, DFNA3, DFNA3A, DFNB1, DFNB1A}, HES1 (hes family bHLH transcription factor 1) [NCBI Gene 3280] {aka HES-1, HHL, HRY, bHLHb39}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, STAT2 (signal transducer and activator of transcription 2) [NCBI Gene 6773] {aka IMD44, ISGF-3, P113, PTORCH3, STAT113}, IL24 (interleukin 24) [NCBI Gene 11009] {aka C49A, FISP, IL10B, MDA7, MOB5, ST16}, PTPN6 (protein tyrosine phosphatase non-receptor type 6) [NCBI Gene 5777] {aka HCP, HCPH, HPTP1C, PTP-1C, SH-PTP1, SHP-1}, POLR2F (RNA polymerase II, I and III subunit F) [NCBI Gene 5435] {aka HRBP14.4, POLRF, RPABC14.4, RPABC2, RPB14.4, RPB6}, KDM5B (lysine demethylase 5B) [NCBI Gene 10765] {aka CT31, JARID1B, MRT65, PLU-1, PLU1, PPP1R98}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, APOF (apolipoprotein F) [NCBI Gene 319] {aka Apo-F, LTIP}, CXCL11 (C-X-C motif chemokine ligand 11) [NCBI Gene 6373] {aka H174, I-TAC, IP-9, IP9, SCYB11, SCYB9B}, IL22 (interleukin 22) [NCBI Gene 50616] {aka IL-21, IL-22, IL-D110, IL-TIF, ILTIF, TIFIL-23}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, MX1 (MX dynamin like GTPase 1) [NCBI Gene 4599] {aka IFI-78K, IFI78, MX, MxA, lncMX1-215}, FOSL1 (FOS like 1, AP-1 transcription factor subunit) [NCBI Gene 8061] {aka FRA, FRA1, fra-1}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, KIR2DL3 (killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3) [NCBI Gene 3804] {aka CD158B2, CD158b, GL183, KIR-023GB, KIR-K7b, KIR-K7c}, PI3 (peptidase inhibitor 3) [NCBI Gene 5266] {aka ESI, SKALP, WAP3, WFDC14, cementoin}, OVOL1 (ovo like transcriptional repressor 1) [NCBI Gene 5017] {aka HOVO1}
- **Diseases:** infections (MESH:D007239), trauma (MESH:D014947), dysregulation (MESH:D021081), Psoriasis (MESH:D011565), psoriatic (MESH:D015535), immune (MESH:D007154), cardiovascular conditions (MESH:D002318), NF1 deficiency (MESH:D009456), metabolic diseases (MESH:D008659), inflammation (MESH:D007249), skin (MESH:D012871), epidermal dysfunction (MESH:D004814), epidermal hyperplasia (MESH:D006965), mediated (MESH:C567355), systemic disease (MESH:D034721)
- **Chemicals:** carnitines (MESH:D002331), glutamine (MESH:D005973), risankizumab (MESH:C000601773), fatty acids (MESH:D005227), organic acids (-), cholesterol (MESH:D002784), linoleic acid (MESH:D019787), citrate (MESH:D019343), infliximab (MESH:D000069285), tryptophan (MESH:D014364), Lipid (MESH:D008055), arginine (MESH:D001120), 5-mC (MESH:D044503), asparagine (MESH:D001216), cysteine (MESH:D003545), arachidonic acid (MESH:D016718), Amino acids (MESH:D000596), guselkumab (MESH:C000588857), 5-hmC (MESH:C011865), trimethylamine-N-oxide (MESH:C005855), trichostatin A. (MESH:C012589), polyunsaturated fatty acids (MESH:D005231), ceramides (MESH:D002518), quinolinic acid (MESH:D017378)
- **Species:** Staphylococcus (genus) [taxon 1279], gut metagenome (species) [taxon 749906], Mus musculus (house mouse, species) [taxon 10090], Candida albicans (species) [taxon 5476], Homo sapiens (human, species) [taxon 9606], Streptococcus (genus) [taxon 1301], Bacillota (clostridial firmicutes, phylum) [taxon 1239], Cutibacterium (genus) [taxon 1912216], Corynebacterium (genus) [taxon 1716], Burkholderia (genus) [taxon 32008], Lactobacillus (genus) [taxon 1578]
- **Cell lines:** HaCaT — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0038)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13034115/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13034115/full.md

## References

138 references — full list in the complete paper: https://tomesphere.com/paper/PMC13034115/full.md

---
Source: https://tomesphere.com/paper/PMC13034115